Cargando…

Soft threshold partial least squares predicts the survival fraction of malignant glioma cells against different concentrations of methotrexate’s derivatives

Chemotherapy appeared to be a significant advancement in cancer research, with fewer side effects. Methotrexate (MTX) is a widely used anticancer drug with strong activity but serious side effects. Several MTX derivatives have been reported, with modifications at various sites to reduce side effects...

Descripción completa

Detalles Bibliográficos
Autores principales: Mehmood, Tahir, Iqbal, Mudassir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8455530/
https://www.ncbi.nlm.nih.gov/pubmed/34548518
http://dx.doi.org/10.1038/s41598-021-97891-3
_version_ 1784570685279961088
author Mehmood, Tahir
Iqbal, Mudassir
author_facet Mehmood, Tahir
Iqbal, Mudassir
author_sort Mehmood, Tahir
collection PubMed
description Chemotherapy appeared to be a significant advancement in cancer research, with fewer side effects. Methotrexate (MTX) is a widely used anticancer drug with strong activity but serious side effects. Several MTX derivatives have been reported, with modifications at various sites to reduce side effects and increase efficacy. The current study uses FTIR spectroscopy to predict the survival fraction of human malignant glioma U87 (MG-U87) cell lines against MTX derivatives. Together with Parent MTX several aldehydes viz. Benzaldehyde, Chlorobenzaldehyde, 2-Chlorobenzaldehyde, 3-Nitrobenzaldehyde, 5-Chloro-2-hydroxybenz-aldehyde, 2-Hydroxy-5-Nitrobenzaldehyde, 2-Thiocarboxyaldehyde, Trans-2-pentenal, and Glutaraldehyde are treated with MTX to obtain MTX derivatives. The prediction of survival fraction of malignant glioma cells is carried out by Lasso, Elastic net and Soft PLS at different concentration levels of synthesized derivatives, including 400 μM, 200 μM, 100 μM, 50 μM, 25 μM and 12.5 μM. The cross-validated prediction error is minimised to optimise spectral wavelength selection and model parameters. It appears that the RMSE computed from test data is significantly varying with the change of models (p = 0.012), with the change of concentrations levels (p [Formula: see text] ) and with the change of combination of models and concentration level (p [Formula: see text] ). StPLS outperforms in predicting survival fraction of glioma cells at the concentration level 50 μM, 100 μM and 400 μM respectively with relative RMSE = 0.1,0.14 and 0.55. Lasso outperforms at the concentration level 12.5 μM, and 200 μM respectively with relative RMSE = 0.4 and 0.14. Elastic net outperforms at the concentration level 25 μM with relative RMSE = 0.8. Consistently appeared influential wavelength identifies the influential functional compounds which best predicts the survival fraction. Hence FTIR appears potential candidate for estimating survival fraction of MTX derivatives.
format Online
Article
Text
id pubmed-8455530
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-84555302021-09-22 Soft threshold partial least squares predicts the survival fraction of malignant glioma cells against different concentrations of methotrexate’s derivatives Mehmood, Tahir Iqbal, Mudassir Sci Rep Article Chemotherapy appeared to be a significant advancement in cancer research, with fewer side effects. Methotrexate (MTX) is a widely used anticancer drug with strong activity but serious side effects. Several MTX derivatives have been reported, with modifications at various sites to reduce side effects and increase efficacy. The current study uses FTIR spectroscopy to predict the survival fraction of human malignant glioma U87 (MG-U87) cell lines against MTX derivatives. Together with Parent MTX several aldehydes viz. Benzaldehyde, Chlorobenzaldehyde, 2-Chlorobenzaldehyde, 3-Nitrobenzaldehyde, 5-Chloro-2-hydroxybenz-aldehyde, 2-Hydroxy-5-Nitrobenzaldehyde, 2-Thiocarboxyaldehyde, Trans-2-pentenal, and Glutaraldehyde are treated with MTX to obtain MTX derivatives. The prediction of survival fraction of malignant glioma cells is carried out by Lasso, Elastic net and Soft PLS at different concentration levels of synthesized derivatives, including 400 μM, 200 μM, 100 μM, 50 μM, 25 μM and 12.5 μM. The cross-validated prediction error is minimised to optimise spectral wavelength selection and model parameters. It appears that the RMSE computed from test data is significantly varying with the change of models (p = 0.012), with the change of concentrations levels (p [Formula: see text] ) and with the change of combination of models and concentration level (p [Formula: see text] ). StPLS outperforms in predicting survival fraction of glioma cells at the concentration level 50 μM, 100 μM and 400 μM respectively with relative RMSE = 0.1,0.14 and 0.55. Lasso outperforms at the concentration level 12.5 μM, and 200 μM respectively with relative RMSE = 0.4 and 0.14. Elastic net outperforms at the concentration level 25 μM with relative RMSE = 0.8. Consistently appeared influential wavelength identifies the influential functional compounds which best predicts the survival fraction. Hence FTIR appears potential candidate for estimating survival fraction of MTX derivatives. Nature Publishing Group UK 2021-09-21 /pmc/articles/PMC8455530/ /pubmed/34548518 http://dx.doi.org/10.1038/s41598-021-97891-3 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Mehmood, Tahir
Iqbal, Mudassir
Soft threshold partial least squares predicts the survival fraction of malignant glioma cells against different concentrations of methotrexate’s derivatives
title Soft threshold partial least squares predicts the survival fraction of malignant glioma cells against different concentrations of methotrexate’s derivatives
title_full Soft threshold partial least squares predicts the survival fraction of malignant glioma cells against different concentrations of methotrexate’s derivatives
title_fullStr Soft threshold partial least squares predicts the survival fraction of malignant glioma cells against different concentrations of methotrexate’s derivatives
title_full_unstemmed Soft threshold partial least squares predicts the survival fraction of malignant glioma cells against different concentrations of methotrexate’s derivatives
title_short Soft threshold partial least squares predicts the survival fraction of malignant glioma cells against different concentrations of methotrexate’s derivatives
title_sort soft threshold partial least squares predicts the survival fraction of malignant glioma cells against different concentrations of methotrexate’s derivatives
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8455530/
https://www.ncbi.nlm.nih.gov/pubmed/34548518
http://dx.doi.org/10.1038/s41598-021-97891-3
work_keys_str_mv AT mehmoodtahir softthresholdpartialleastsquarespredictsthesurvivalfractionofmalignantgliomacellsagainstdifferentconcentrationsofmethotrexatesderivatives
AT iqbalmudassir softthresholdpartialleastsquarespredictsthesurvivalfractionofmalignantgliomacellsagainstdifferentconcentrationsofmethotrexatesderivatives